Eur Rev Med Pharmacol Sci 2016; 20 (6): 999-1000

Peripheral blood used in place of bone marrow aspirate for detection of translocation t(11;14) status during minimal residual disease monitoring is cost-effectiveness

A. Lleshi, A. Rainone

Department of Medical Oncology, National Cancer Institute, Aviano (PN) Italy. rainoneaniello@gmail.com

Free PDF Download

To cite this article

A. Lleshi, A. Rainone
Peripheral blood used in place of bone marrow aspirate for detection of translocation t(11;14) status during minimal residual disease monitoring is cost-effectiveness

Eur Rev Med Pharmacol Sci
Year: 2016
Vol. 20 - N. 6
Pages: 999-1000

Keywords Related articles:

  1. Comment on “Peripheral blood used in place of bone marrow aspirate for detection of translocation t(11;14) status during minimal residual disease monitoring is cost-effectiveness”
  2. Quantitative PCR detection of t(11;14) bcl-1/JH in mantle cell lymphoma patients: comparison of peripheral blood and bone marrow aspirate samples
  3. From stem cell to solid organ. Bone marrow, peripheral blood or umbilical cord blood as favorable source?
  4. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia
  5. Bone marrow aspirate and bone allograft to treat acetabular bone defects in revision total hip arthroplasty: preliminary report